The nation of Zimbabwe has declined a significant American health deal worth $367m (£272m) spanning five years over Washington's request for sensitive information.
This rejection was revealed following a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesperson has since explained that the US was demanding access to health data for research and commercial purposes but was not willing to share the resulting advantages from any future medical innovations.
"We are forced to start the difficult and regrettable task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for more negotiations to find a deal acceptable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump argued its spending was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and accountability.
As per reports, 16 nations in Africa have to date agreed to similar agreements, constituting over $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on HIV treatment via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data over an extended period, with no equivalent guarantee of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," Mangwana explained.
"In essence, our country would supply the raw materials for medical research without any certainty that the final treatments would be accessible to our people should a future health crisis emerge."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously set up via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country provides its samples, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body stated it acknowledged the government's concerns, but urged that negotiations must proceed given that much of the country's HIV programmes depended on international support.
"If technical issues exist, such as those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
The situation highlights the ongoing challenges between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.